
Thiogenesis Therapeutics, Corp. — Investor Relations & Filings
Thiogenesis Therapeutics, Corp. is a clinical-stage biotechnology company specializing in the development of New Chemical Entities (NCEs), specifically novel thiol-based prodrugs. These next-generation sulfur-containing therapeutics are designed to restore redox balance and mitigate inflammation, key drivers in inherited and acquired mitochondrial diseases. The company's lead candidate, TTI-0102, is a novel cysteamine prodrug engineered to overcome the limitations of legacy thiol therapies, offering enhanced tolerability, bioavailability, and improved dosing profiles. TTI-0102 is currently being evaluated for unmet pediatric medical needs, including nephropathic cystinosis (with a pivotal Phase 3 trial planned following an expected 2026 IND filing), MELAS (in Phase 2), and other conditions such as Leigh syndrome spectrum.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| News release - English.pdf | 2026-05-11 | English | |
| ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF | 2026-04-30 | English | |
| 52-109FV1 - Certification of annual filings - CEO (E).pdf | 2026-04-30 | English | |
| Annual MD&A - English.pdf | 2026-04-30 | English | |
| News release - English.pdf | 2026-04-16 | English | |
| News release - English.pdf | 2026-04-16 | English |
Browse filings by year
8 yearsMarket data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Gemina Laboratories Ltd.
Biotechnology company developing IVD and biosensing solutio…
|
GLAB | CA | Manufacturing |
|
GemVax & KAEL Co.,Ltd.
Clinical-stage biopharma developing therapeutics for neurod…
|
082270 | KR | Manufacturing |
|
Gencurix Inc.
Develops and commercializes diagnostic solutions for precis…
|
229000 | KR | Manufacturing |
|
GENEDRIVE PLC
Develops rapid, point-of-care pharmacogenetic testing platf…
|
GDR | GB | Manufacturing |
|
GENELUX Corp
Clinical-stage biopharma developing oncolytic viral immunot…
|
GNLX | US | Manufacturing |
|
GENEMATRIX INC.
Develops multiplex PCR diagnostic products for infectious d…
|
109820 | KR | Manufacturing |
|
Generation Bio Co.
Develops siRNA therapeutics delivered via ctLNPs for T cell…
|
GBIO | US | Manufacturing |
|
GENETIC SIGNATURES LIMITED
Molecular diagnostics company using proprietary 3base techn…
|
GSS | AU | Manufacturing |
|
Genexine, Inc.
Clinical-stage biotech developing long-acting therapeutics …
|
095700 | KR | Manufacturing |
|
Genfit S.A.
Biopharmaceutical firm developing therapies and diagnostics…
|
GNFT | US | Manufacturing |
Thiogenesis Therapeutics, Corp. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/47770/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=47770 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=47770 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=47770 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 47770}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Thiogenesis Therapeutics, Corp. (id: 47770)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.